IP21: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology III
Friday, May 15, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
146B
Poster and Podium Sessions
BPHNew Technologies/Instruments/Devices
Friday, May 15
IP21-01: 24-MONTH OUTCOMES FROM A RANDOMIZED, SHAM CONTROLLED STUDY EVALUATING A NOVEL PROSTATIC URETHRAL STENT FOR THE TREATMENT OF BPH
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Steven Kaplan · Icahn School of Medicine at Mount Sinai
IP21-02: 3-MONTH OUTCOMES FROM A PROSPECTIVE, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING A NOVEL DELIVERY SYSTEM WHEN DEPLOYING THE PROVEE PROSTATIC URETHRAL STENT FOR THE TREATMENT OF BPH
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Steven Kaplan · Icahn School of Medicine at Mount Sinai
IP21-03: A randomized trial comparing iTind versus UroLift (MT-08) - Interim report findings.
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Bilal Chughtai · Northwell Health
IP21-04: Introduction of a Structured Reporting Protocol and Surgical Checklist for Rezum Water Vapor Therapy (VAPOR-SRP)
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Viktor Alargkof · University Hospital Basel
IP21-05: Assessing Trends in Complications after BPH Treatment among Community Practice Using the American Urological Association Quality Registry (AQUA)
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
John Ernandez · Brigham and Women’s Hospital
IP21-06: Current Trends in Hospital-Based Surgical Modalities for Benign Prostatic Hyperplasia: 12 Years of National Surgical Quality Improvement Program Data
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Richard Berman · Columbia University Vagelos College of Physicians and Surgeons
IP21-07: Surgical Regret Following Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia – The Paradox of Choice
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Timothy Han · Loyola University Medical Center
IP21-08: Risk of death after aquablation and minimally invasive surgical treatment for LUTS/BPH: analysis of the Food and Drug Administration's Manufacturer and User Facility Device Experience Database
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Marta Santioni
IP21-09: Does Surgery for Benign Prostatic Hyperplasia Affect the Risk of Repeat TURBT?
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Nicholas Khoo
IP21-10: Real-World Evidence of Fall Risk among Patients with Benign Prostatic Hyperplasia Treated with Medication versus Early Surgical Intervention
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Bilal Chughtai · Northwell Health
IP21-11: Novel Peptide Hydrogel (PuraStat®) for Hemostasis During Aquablation®: A Prospective Safety and Feasibility Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Alexandre Armache
IP21-12: Predictors of Overactive Bladder Recovery After Robot-Assisted Simple Prostatectomy: Insights from a Prospective Single-Center Cohort
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Alfredo Maria Bove · "Regina Elena" National Cancer Institute
IP21-13: Urinary outcomes of International Prostate Symptom Score phenotypes following transurethral resection of the prostate: a secondary analysis of the Prostate Cancer Prevention Trial
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Connor Chestnut · University of Washington
IP21-14: A Systematic Review and Updated Network Meta-Analysis to Rank the Effectiveness of Bladder Outlet Obstruction Surgical Procedures
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Nathan Joseph Godinho · Federal University of Minas Gerais
IP21-15: Early Clinical Experience with the ALPFA GRAIL System for the Minimally Invasive Treatment of Benign ProstaticHyperplasia
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Silvia Secco · ASST Great Metropolitan Niguarda
IP21-16: Prostatic Urethral Lift as an Alternative to Combination Medical Therapy in LUTS/BPH: Early Results of the First Prospective Randomized trial (The CombLift Study)
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Yuri Botelho
IP21-17: A First in Human Dose Safety and Feasibility Dose Escalation Study of Intraprostatic Drug Eluting Bioabsorbable Implants for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Lodewikus Vermeulen · Tauranga Urology, New Zealand
IP21-18: Long-Term Outcomes and Retreatment Rates Following Prostatic Artery Embolization (PAE) – A Retrospective Analysis with A Median Follow-Up of 9.0 Years
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Peter Chiu · The Chinese University of Hong Kong
IP21-19: Aquablation of the Prostate: The Untold Story of Long-Term Complications
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Rinat Lasmanovich · Sheba Medical Center
IP21-20: Patient-level cost comparison of Aquablation versus HoLEP; Aquablation is the financially favourable choice
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Shiv Sarna · University College London Hospital
IP21-21: Long-Term Effectiveness of a New Drug-Device Combination for BPH Treatment: Final Five-Year Results of Optilume BPH in the EVEREST Study
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Steven Kaplan · Icahn School of Medicine at Mount Sinai
IP21-22: Five-Year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-World Analysis Using Epic Cosmos
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Luca Morgantini · University of Illinois at Chicago
IP21-23: Clinical evaluation of AI-based software for predicting pharmacologic response in benign prostatic hyperplasia
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Michael Koo · Samsung medical center
IP21-24: A Novel Metal-Free Sling Approach for Benign Prostatic Hyperplasia: Early Results of the Progator Procedure with High Ejaculatory Preservation
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Jun Hee Lee
IP21-25: A Propensity Matched Analysis of Transurethral Robotic Waterjet Therapy systems: 1st Generation Platform (AquaBeam) Versus 2nd Generation AI-Powered Platform (HYDROS)
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Laurence Hou · Hackensack University Medical Center
IP21-26: Value of Intentional Retrieval of Prostatic Urethral Implant for BPH: Technique and outcomes from the Expander-2 Trial
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Daniel Rukstalis · Virginia Tech Carilion School of Medicine
IP21-27: Prostatic artery embolization (PAE) in elderly and frail patients: clinical outcomes and anatomical correlations from a single center cohort
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Tommaso Ceccato
IP21-28: Optilume BPH: Combined outcomes from the PINNACLE and EVEREST Studies
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Adel Arezki · McGill University
IP21-29: Predictors of Treatment Regret after Laser Enucleation of the Prostate for Benign Prostatic Obstruction
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Ilaria Elena Zais
IP21-30: Age-Based Outcomes Following Optilume BPH Therapy: A Sub-Analysis of the EVEREST and PINNACLE Studies
Friday, May 15, 2026 3:30 PM to 5:30 PM
146B
Adel Arezki · McGill University
